Personalized mRNA Vaccine for Melanoma: Why We Are Excited
Every so often, news comes out of the cancer world that makes our whole team stop and smile. This month brought one of those moments. Merck and Moderna announced results for their personalized mRNA vaccine for melanoma. Given together with immunotherapy, the vaccine met its goals in a large Phase 3 trial. It reduced the chance of melanoma coming back after surgery. For those of us who care for cancer patients every day, and for the many survivors in our community, this is the progress we have hoped to see for years.
What Merck and Moderna Announced
On August 19, 2026, Merck and Moderna shared topline results from their Phase 3 trial, called INTerpath-001. The trial enrolled 1,137 patients with higher-risk melanoma (stage IIB through IV). All of them had their tumors completely removed with surgery. Even after successful surgery, these patients face a real risk of the cancer returning. Most recurrences happen within the first two to three years.
This is the first time an mRNA-based cancer therapy has succeeded in a Phase 3 trial. It is also the first Phase 3 study to show a meaningful improvement over Keytruda alone for these patients after melanoma surgery. The companies plan to present the full data at an upcoming medical meeting. They will also begin conversations with regulators about approval.
Why This Matters Beyond Melanoma
Here is why this news resonates so deeply in our practice: the approach is not really about melanoma. It is about a strategy. Doctors read an individual patient’s tumor and build a treatment for that exact cancer. If the strategy keeps proving itself, the same technology could extend to many other cancers. Studies of this personalized approach are already underway in other tumor types. Everyone in the cancer world is watching to see whether these results repeat, including in breast cancer.
Many of our patients have been through breast cancer treatment and reconstruction. For them, the idea of a personalized vaccine that helps keep cancer from coming back is incredibly hopeful. As Dr. Peled put it, this is something all of us in the cancer world have hoped for for so long, and we cannot wait to see where it goes.
What You Can Do Today
Personalized vaccines still need to finish trials and regulatory review. In the meantime, the fundamentals of melanoma prevention and early detection have not changed:
- Protect your skin from the sun with daily broad-spectrum sunscreen, hats, and protective clothing.
- Check your own skin regularly and learn the warning signs of changing moles.
- See a dermatologist for a full-body skin exam, especially if you have a personal or family history of skin cancer.
- If you have had melanoma, keep up with your recommended follow-up schedule.
If you have questions about your own cancer care, survivorship, or reconstruction options, we are always here to talk them through. Schedule an in-person or virtual consultation with our team.
Striving to get you better than you’ve ever been.
Sources: Merck and Moderna Phase 3 INTerpath-001 announcement (August 19, 2026); KEYNOTE-942 five-year follow-up, Journal of Clinical Oncology / 2026 ASCO Annual Meeting.